Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects (narrative) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
QoL · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Abdominal pain · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: abdominal pains compared with placebo (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · Catuama
'Catuama' herbal compound (Spanemberg 2012) contributes to the dietary supplements short-term symptom-relief comparison (insufficient/contradictory); no separate estimate reported.
1 study · 72 participants
GRADE not reported
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether physical barriers (tongue protector + reinforced self-control… changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: headache · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: headache compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Weight gain · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (Catuama herbal compound) changes adverse effects: weight gain compared with placebo (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · lycopene
Lycopene (Cano-Carrillo 2014) contributes to the dietary supplements short-term symptom-relief comparison (12 RCTs, insufficient/contradictory); no separate lycopene symptom-relief estimate reported.
1 study · 50 participants
GRADE not reported
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · topical urea 10%
Topical urea 10% (Alvarenga da Silva 2014) contributes to the topical treatments short-term symptom-relief comparison (insufficient/contradictory); no separate estimate reported.
1 study · 38 participants
GRADE not reported
Control of bleeding (cure or improvement to acceptable level) At 2 years · women with heavy menstrual bleeding
Surgery probably leads to higher control of bleeding (cure or improvement to acceptable level) At 4… compared with oral medication (moderate certainty).
3 findings from 1 review
RR 2.66 [1.94, 3.64]
1 study · 186 participants
Moderate
RR 1.29 [1.06, 1.57]
1 study · 173 participants
Low
RR 1.14 [0.97, 1.34]
1 study · 140 participants
Very low
Overall satisfaction with treatment At 2 years · women with heavy menstrual bleeding
Surgery probably leads to higher overall satisfaction with treatment At 2 years compared with oral medication (moderate certainty).
1 finding from 1 review
Overall satisfaction with treatment At 5 years · women with heavy menstrual bleeding
It is very uncertain whether surgery changes overall satisfaction with treatment At 5 years compared with oral medication (very low certainty).
1 finding from 1 review
Adverse events at 4 months · women with heavy menstrual bleeding
Surgery probably leads to lower adverse events at 4 months compared with oral medication (moderate certainty).
1 finding from 1 review
Adverse events: Specific ‐ prolactin‐related ‐ long term It is unclear how adverse events were reported · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related ‐ long term It is… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Weight gain · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ weight increase ‐ long term It is unclear… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Adverse events: Nervous system disorders (inc. EPS) ‐ long term It is unclear how adverse events were reported · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Nervous system disorders (inc. EPS) ‐ long term It… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review